Metastatic or Recurrent TNBC

ASCO 2023: Junshi Biosciences Unveils Breakthrough Phase III Trial Results: Toripalimab Combination Therapy Shows Remarkable Efficacy in Metastatic or Recurrent TNBC

ASCO 2023: Toripalimab Combination Therapy – A Breakthrough for TNBC

SG Tylor

ABSTRACT NUMBER – LBA1013 Combining taxanes-based chemotherapy with checkpoint blockade yields diverse outcomes in the first-line metastatic triple-negative breast cancer ...